Currently there is no FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (“LBP”) and has received Fast Track Status from the FDA; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Fully comply with all laws, regulations and Scilex Policies, Code of Conduct, all privacy and data guidelines, relevant state and federal laws and regulations as well as the Company’s policies and procedures in connection with the performance of the job function, including, but not limited to, the Federal Food, Drug, and Cosmetic Act, the Prescription Drug Act, Marketing Act, the PhRMA Code related to interactions w/healthcare providers, and the Federal Anti-Kickback Statute.